CN106890312A - 一种适用于肝癌患者的肠内营养剂及其制备方法 - Google Patents
一种适用于肝癌患者的肠内营养剂及其制备方法 Download PDFInfo
- Publication number
- CN106890312A CN106890312A CN201510945183.9A CN201510945183A CN106890312A CN 106890312 A CN106890312 A CN 106890312A CN 201510945183 A CN201510945183 A CN 201510945183A CN 106890312 A CN106890312 A CN 106890312A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- nutritional agents
- elental
- fat
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 20
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000016709 nutrition Nutrition 0.000 claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 16
- 235000010755 mineral Nutrition 0.000 claims abstract description 16
- 239000011707 mineral Substances 0.000 claims abstract description 16
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 14
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 229920002307 Dextran Polymers 0.000 claims abstract description 9
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 9
- 239000012138 yeast extract Substances 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 235000018102 proteins Nutrition 0.000 claims description 21
- 235000019197 fats Nutrition 0.000 claims description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 235000014633 carbohydrates Nutrition 0.000 claims description 17
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 16
- 102000004407 Lactalbumin Human genes 0.000 claims description 12
- 108090000942 Lactalbumin Proteins 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 239000000828 canola oil Substances 0.000 claims description 10
- 235000019519 canola oil Nutrition 0.000 claims description 10
- 235000021323 fish oil Nutrition 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 9
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 239000001506 calcium phosphate Substances 0.000 claims description 9
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 9
- 235000011010 calcium phosphates Nutrition 0.000 claims description 9
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 9
- 229960000359 chromic chloride Drugs 0.000 claims description 9
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 9
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims description 9
- 229960003512 nicotinic acid Drugs 0.000 claims description 9
- 239000011664 nicotinic acid Substances 0.000 claims description 9
- 229940055726 pantothenic acid Drugs 0.000 claims description 9
- 235000019161 pantothenic acid Nutrition 0.000 claims description 9
- 239000011713 pantothenic acid Substances 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000011684 sodium molybdate Substances 0.000 claims description 9
- 235000015393 sodium molybdate Nutrition 0.000 claims description 9
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 8
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 235000019743 Choline chloride Nutrition 0.000 claims description 8
- -1 carbon water Compound Chemical class 0.000 claims description 8
- 229960003178 choline chloride Drugs 0.000 claims description 8
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 8
- 239000000395 magnesium oxide Substances 0.000 claims description 8
- 239000011772 phylloquinone Substances 0.000 claims description 8
- 239000011655 sodium selenate Substances 0.000 claims description 8
- 235000018716 sodium selenate Nutrition 0.000 claims description 8
- 229960001881 sodium selenate Drugs 0.000 claims description 8
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 8
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 8
- 229960001763 zinc sulfate Drugs 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229940099596 manganese sulfate Drugs 0.000 claims description 7
- 239000011702 manganese sulphate Substances 0.000 claims description 7
- 235000007079 manganese sulphate Nutrition 0.000 claims description 7
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- 239000011790 ferrous sulphate Substances 0.000 claims description 6
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 6
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019742 Vitamins premix Nutrition 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 239000007961 artificial flavoring substance Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 210000000593 adipose tissue white Anatomy 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 229940019204 ferrous sulfate 50 mg Drugs 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000009499 Vanilla fragrans Nutrition 0.000 claims 1
- 244000263375 Vanilla tahitensis Species 0.000 claims 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- WKZFQFQFYZJKPR-UHFFFAOYSA-N butanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCC(O)=O WKZFQFQFYZJKPR-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 6
- 244000241872 Lycium chinense Species 0.000 abstract description 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 11
- 125000001931 aliphatic group Chemical group 0.000 description 9
- 241000209094 Oryza Species 0.000 description 7
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- KNLQKHUBPCXPQD-UHFFFAOYSA-N manganese;sulfuric acid Chemical compound [Mn].OS(O)(=O)=O KNLQKHUBPCXPQD-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- PRKRTJSKTGAVMH-UHFFFAOYSA-N selenic acid;sodium Chemical compound [Na].O[Se](O)(=O)=O PRKRTJSKTGAVMH-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- WQSRXNAKUYIVET-UHFFFAOYSA-N sulfuric acid;zinc Chemical compound [Zn].OS(O)(=O)=O WQSRXNAKUYIVET-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种适用于肝癌患者的肠内营养制剂及其制备方法,按所述营养剂1000mL计,所述营养剂成分包含:蛋白质50-75g、脂肪30-48g、碳水化合物158-186g、膳食纤维9-18g、牛磺酸171-319mg、L-肉碱100-156mg、核苷酸(来源于酵母抽出物)300-419mg、酵母β-葡聚糖150-320mg、枸杞多糖0.8-1.5g、维生素0.5-2g、矿物质13.8-25.8g、水650-710g。本配方包含人体所需7大营养素,同时含有药食同源-枸杞子中的生物活性成分,多种药理营养素,适合肝癌患者食用。依据该配方制成的液态制剂,可直接食用,吸收快速;支链氨基酸占蛋白质总量的35%,减少肝脏负担。
Description
技术领域
本发明属于医药技术领域,具体涉及一种适用于肝癌患者的肠内营养剂及其制备方法。
背景技术
我国每年新发肝癌患者约35万,死亡约32万,位居中国恶性肿瘤发生率第三位,死亡率第二位。其中,原发性肝细胞癌占90%,绝大多数合并乙肝和不同程度的肝硬化。另据国际肿瘤研究中心(IARC)估计,全球55%的肝癌患者发生在中国。
肝癌患者由于摄入量少(营养物质摄入减少、恶心呕吐、食欲减退、消化道黏膜病变、胆汁减少等)、出量及消耗增多(恶性肿瘤消耗、消化道出血、腹腔感染、毒血症、组织分解、大量引流腹腔积液、内分泌紊乱、免疫系统激活等)、正常肝细胞功能受损、机体适应能力下降等因素,多数都伴有蛋白质-能量营养不良,其原因包括:①食物摄入减少,营养物质丢失过多;②合成蛋白质能力下降,血清蛋白质水平降低,影响正常血浆胶体渗透压及某些激素的生成、微量元素的利用等,从而影响机体的营养状态;③营养物质代谢异常:糖的储存和氧化降低;脂肪酸和酮体的产生和利用障碍;蛋白质分解代谢增加,氮量在体内消耗明显。
营养支持治疗不仅能满足肝癌患者能量需求,还可促进受损肝细胞修复再生,改善肝脏代谢,增强解毒能力,减少毒物生成;并且可增强机体免疫功能,提高其抵抗力。肠内营养是临床营养支持的重要手段,有助于维持肠粘膜细胞结构与功能的完整。当患者需要营养支持且具有完整或者部分胃肠道功能时,应首选肠内营养途径。
目前,我国的专利已有供肝病患者使用的食品配方,如专利号CN101496578“一种供肝病患者食用含短肽的特殊膳食用食品配方”、专利号CN103431275B“一种供肝病患者食用的五谷杂粮全营养配方食品”、专利号CN104082656A“一种适合肝病病人的营养膳及其制作方法”、专利号CN104223057A“肝病全营养配方食品”等,但这些产品配方主要针对肝病,设计较广,尚缺乏针对肝癌患者的全营养制剂。依据癌细胞的异常代谢,根据肝癌患者的代谢特点和营养需求,有针对性地开发适用于肝癌患者的肠内营养产品,为肝癌患者提供合理、适当的营养,有助于提高临床治疗耐受性、提高生活质量。
发明内容
本发明的目的是提供一种适合肝癌患者的营养剂及其制备方法,以满足肝癌患者对营养素的特殊需求。
本发明的上述目的是通过以下技术方案实现的:
本发明提供一种用于肝癌患者的肠内营养剂,所述营养剂包含蛋白质、脂肪、碳水化合物、膳食纤维、牛磺酸、L-肉碱、酵母抽出物、酵母β-葡聚糖、枸杞多糖、维生素、矿物质和水;
其中,所述蛋白质包含乳清蛋白和支链氨基酸(亮氨酸、缬氨酸和异亮氨酸);
所述脂肪包含芥花油、中链(C6-C12)甘油三酯和鱼油;
所述碳水化合物包含水解米粉、麦芽糊精;
所述膳食纤维包含低聚果糖;
所述维生素包含维生素A、维生素D、维生素E、维生素K1、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、生物素、氯化胆碱、烟酸、叶酸和泛酸;
所述矿物质包含L-乳酸钙、氯化钠、磷酸氢二钾、硫酸铜、氧化镁、硫酸亚铁、硫酸锌、硫酸锰、磷酸钙、碘化钾、氯化钾、硒酸钠、钼酸钠、三氯化铬;
优选地,按所述营养剂1000mL计,所述营养剂包含:蛋白质50-75g、脂肪30-48g、碳水化合物158-186g、膳食纤维9-18g、牛磺酸171-319mg、L-肉碱100-156mg、核苷酸(来源于酵母抽出物)300-419mg、酵母β-葡聚糖150-320mg、枸杞多糖0.8-1.5g、维生素0.5-2g、矿物质13.8-25.8g、水650-710g;
优选地,按所述营养剂1000mL计,所述营养剂包含:蛋白质65g、脂肪36g、碳水化合物178g、膳食纤维13g、牛磺酸200mg、L-肉碱130mg、核苷酸320mg、酵母β-葡聚糖180mg、枸杞多糖1g、维生素1g、矿物质18.9g、水686g。
按所述营养剂1000mL计,所述蛋白质来源于乳清蛋白56.5-78g、支链氨基酸4.8-12.6g;优选地,所述蛋白质来源于乳清蛋白73.5g、支链氨基酸6.4g。
按所述营养剂1000mL计,所述脂肪来源于芥花油16.2-19.4g、中链甘油三酯13.3-16.4g、鱼油6.5-14.4g;优选地,所述脂肪来源于芥花油18.0g、中链甘油三酯16.0g、鱼油10g。
按所述营养剂1000mL计,所述碳水化合物来源于水解米粉80.5-125g、麦芽糊精76.8-112.5g;优选地,所述碳水化合物来源于水解米粉95.0g、麦芽糊精90.0。
按所述营养剂1000mL计,所述维生素包含维生素A 0.65-1.5mg RE、维生素D 9.2-20.1μg、维生素E 45-71mgα-TE、维生素K185-120μg、维生素B1 1-4mg、维生素B2 1.2-3.1mg、维生素B6 2-5.3mg、维生素B12 5.2-9.3μg、维生素C 176-258mg、生物素340-425μg、氯化胆碱352-486mg、烟酸22.3-28mg、叶酸384-610μg、泛酸9.2-16mg;
优选地,所述维生素来源于维生素A 0.94mg RE、维生素D 12.5μg、维生素E 117mgα-TE、维生素K1 100μg、维生素B1 1.88mg、维生素B2 24.9mg、维生素B2 2.5mg、维生素B127.6μg、维生素C 515mg、生物素377μg、氯化胆碱374mg、烟酸25mg、叶酸380μg、泛酸12.6mg。
按所述营养剂1000mL计,所述矿物质来源L-乳酸钙2.1-2.8g、氯化钠2.8-3.5g、磷酸氢二钾0.8-1.35g、硫酸铜1.5-2.4mg、氧化镁0.38-0.54g、硫酸亚铁42-63mg、硫酸锌88-116mg、硫酸锰16.8-23.2mg、磷酸钙1-1.8g、碘化钾0.22-0.36mg、氯化钾0.42-0.54g、硒酸钠0.48-0.67mg、钼酸钠0.38-0.52mg、三氯化铬4.8-7.2mg;
优选地,按所述营养剂1000mL计,所述矿物质来源L-乳酸钙2.5g、氯化钠3.2g、磷酸氢二钾1.2g、硫酸铜2mg、氧化镁0.5g、硫酸亚铁50mg、硫酸锌100mg、硫酸锰20mg、磷酸钙1.45g、碘化钾0.3mg、氯化钾0.48g、硒酸钠0.55mg、钼酸钠0.45mg、三氯化铬6mg;
优选地,所述营养剂还包含乳化剂,其选自卵磷脂、单,双甘油脂肪酸酯和琥珀酸单甘油酯中的一种或多种;
优选地,按所述营养剂1000mL计,所述营养剂包含乳化剂3.3g;
优选地,所述营养剂还包含调味品,其选自天然香料和人工香料中的一种或两种。
本发明所述营养剂包含的蛋白质、脂肪和碳水化合物的供能比为16-22%∶20-28%∶50-64%,优选地,所述营养剂包含的蛋白质、脂肪和碳水化合物的供能比为20%∶25%∶55%。
本发明还提供一种本发明所述肠内营养剂的制备方法,制备方法包括将上述各成分混合均匀,制成均匀乳液;
优选地,本发明所述肠内营养剂的制备方法包括以下步骤:
(1)制备以下溶液:
溶液A:由脂肪(芥花油、中链甘油三酯、鱼油)、乳化剂和脂溶性维生素预混料组成,其中脂溶性维生素预混料由维生素A、维生素D、维生素E、维生素K1组成;
溶液B:由蛋白质(乳清蛋白、支链氨基酸)和水组成;
溶液C:由水、碳水化合物(水解米粉、麦芽糊精)、膳食纤维(低聚果糖)、枸杞多糖和浓度为35%的氢氧化钾组成;
溶液D:由非脂溶性维生素(维生素C、氯化胆碱、烟酸、维生素B12、泛酸、维生素B1、维生素B6、维生素B2、叶酸、生物素)、酵母抽出物、牛磺酸、L-肉碱和水组成;
溶液E:由矿物质和水组成,优选由L-乳酸钙、氯化钠、磷酸氢二钾、硫酸铜、氧化镁、硫酸亚铁、硫酸锌、硫酸锰、磷酸钙、碘化钾、氯化钾、硒酸钠、钼酸钠、三氯化铬和水组成;
溶液F:由水和调味剂组成,优选由水、天然香料和人工香料组成;
将溶液A、B、C、D、E和F混合后在55-65℃下搅拌,调节pH至6.5-6.8;
(2)将步骤(1)得到的混合物加热至70-75℃,0.1-0.2MPa下脱气,后于8-10MPa下乳化后加热至98-102℃,后加热至146-147℃,保持3-8秒;
(3)将步骤(2)得到的混合物冷却至98-102℃;基板散热降温至70-75℃。
(4)在氮气的保护下,将步骤(3)得到的混合物在30-50MPa压力下均质,后在70-80℃下保持13-20秒,后冷却至2-6℃,即得。
本发明所述制备的肠内营养剂治疗肝癌中的用途。
本发明所述肠内营养剂包含人体需要的七大营养素,即碳水化合物、脂肪、蛋白质、维生素、矿物质、水和膳食纤维,符合肝癌患者代谢特点,优选地,所述营养剂包含的蛋白质、脂肪和碳水化合物的供能比为20%∶25%∶55%。
本发明所述肠内营养剂的蛋白质来源于乳清蛋白和支链氨基酸,其中,乳清蛋白为优质蛋白质,有助于增加蛋白质合成、预防分解代谢,促进细胞与组织的修复,有利于增强机体免疫力,降低术后感染风险,改善肿瘤恶液质等虚弱症状。乳清蛋白中富含支链氨基酸(包括缬氨酸、亮氨酸、异亮氨酸),本发明中额外添加支链氨基酸,使支链氨基酸占蛋白质含量的35%,支链氨基酸有助于减缓肝癌细胞进展和降低肝癌患者介入术后复发率。
本发明所述肠内营养剂中,所述营养剂包含的中链脂肪酸、单不饱和脂肪酸、ω-3脂肪酸和ω-6脂肪酸的供能比为2∶2∶1∶2。其中,中链脂肪酸主要来源于中链甘油三酯,具有吸收速度快的优势,是一种能快速提供能量的养分,通常仅需几分钟中链脂肪酸就能直接从肠道上皮细胞吸收,再通过肝门静脉进入血液循环。相比之下,长链脂肪酸要在肠道上皮细胞里重新与甘油结合成甘油三酯,再与载脂蛋白、磷脂和胆固醇形成乳糜微粒,而后才能经淋巴系统进入血液循环,需3~4个小时才能完成。单不饱和脂肪酸主要来源于芥花油,是一种人体必需脂肪酸。ω-3脂肪酸主要来源于鱼油,本发明所述营养剂中提高了ω-3脂肪酸的含量,使ω-3脂肪酸和ω-6脂肪酸的比例为1∶2【世界卫生组织(WHO)推荐正常饮食两者的比例在1∶4-1∶6范围内】。根据脂肪酸与炎症的关系,ω-6脂肪酸属于致炎脂肪酸,ω-3脂肪酸属于抑炎脂肪酸,提高ω-3脂肪酸的含量有助于抑制肿瘤患者的体重下降,增加瘦体重,改善机能。
本发明所述肠内营养剂的碳水化合物来源于水解米粉和麦芽糊精,水解米粉有利于消化吸收,且具有更好的耐受性;膳食纤维来源于低聚果糖,有助于维持胃肠道的功能。
本发明肠内营养剂包含枸杞多糖,枸杞多糖是药食同源-枸杞子的主要功效成分,近年来研究表明枸杞多糖能够抑制肝癌细胞的生长,且具有增加免疫能力、抗氧化和延缓衰老、抗肿瘤、神经保护、抗辐射、保护生殖系统等功能。
本发明肠内营养剂包含酵母β-葡聚糖,是从酵母细胞壁中提取的一种具有增强免疫力的多糖。它能够活化巨噬细胞、嗜中性粒细胞等,因此能提高白细胞素、细胞分裂素和特殊抗体的含量,全面刺激机体的免疫系统;酵母β-葡聚糖能增强血细胞的生成活性,包括粒细胞的生成、单核白细胞以及红细胞的生成,从而导致更好地从辐射中得到恢复;酵母β-葡聚糖能够显著降低人体甘油三脂水平、降低LDL(低密度脂蛋白)水平,并升高HDL(高密度脂蛋白)水平,有效预防冠心病、动脉硬化等心脑血管疾病。
本发明肠内营养剂包含牛磺酸。牛磺酸是人体不可缺少的氨基酸,具有维持正常视觉功能、维持渗透压平衡、维持细胞膜稳定、降血糖、保护组织缺血再灌注损伤、提高机体免疫力、调节脂类分泌、保护心肌细胞等广泛的生物学作用。牛磺酸可增强机体免疫力以及影响抗肿瘤药物的细胞摄入和外排,继而减少因抗肿瘤药物而产生的不良反应。此外,牛磺酸还有助于帮助细胞膜形成及胆酸进行脂肪乳化。
本发明肠内营养剂包含L-肉碱,有利于促进脂肪酸的氧化利用,提高脂肪供能效率,同时可以显著改善患者的疲劳感,从而提高生活质量。
本发明肠内营养剂包含核苷酸(来源于酵母抽出物),其通过参与细胞代谢与更新,有利于增强机体免疫力、维持肠道正常菌群的消化和吸收功能,此外,还具有明显的抗辐射、明显增强机体对外界的应激能力。
具体实施方式
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。
1、原料投料如表1所示:
表1:本发明所述营养剂的制备原料
2、制备方法:
(1)制备以下溶液:
溶液A:由芥花油、中链甘油三酯、鱼油、乳化剂(卵磷脂、单,双甘油脂肪酸酯、琥珀酸单甘油酯)和脂溶性维生素预混料(维生素A、维生素D、维生素E、维生素K)组成;
溶液B:由乳清蛋白、支链氨基酸和水组成;
溶液C:由水、麦芽糊精、水解米粉、低聚果糖、枸杞多糖和浓度为35%的氢氧化钾组成;
溶液D:由非脂溶性维生素(维生素C、氯化胆碱、烟酸、维生素B12、泛酸、维生素B1、维生素B6、维生素B2、叶酸、生物素)、酵母抽出物、牛磺酸、L-肉碱和水组成;
溶液E:由L-乳酸钙、氯化钠、磷酸氢二钾、硫酸铜、氧化镁、硫酸亚铁、硫酸锌、硫酸锰、磷酸钙、碘化钾、氯化钾、硒酸钠、钼酸钠、三氯化铬和水组成;
溶液F:由水、天然香料和人工香料组成;
将溶液A、B、C、D、E和F混合后在55-65℃下搅拌,调节pH至6.5-6.8;
(2)将步骤(1)得到的混合物加热至70-75℃,0.1-0.2MPa下脱气,后于8-10MPa下乳化后加热至98℃,后加热至146-147℃,保持3-8秒;
(3)将步骤(2)得到的混合物冷却至98-102℃;基板散热降温至70-75℃。
(4)氮气保护下,将步骤(3)得到的混合物在30-50MPa压力下均质,后在70-80℃下保持13-20秒,后冷却至2-6℃后放入接收罐储存;通过灌装机,将接收罐内溶液灌入瓶中,并密封其灌入口;对产品进行灭菌、液位打查、真空度检查,然后包装,得到本品。
3、检测结果:
本实施例制备得到的肠内营养剂检测结果如表2:
表2:本发明所述营养剂检测结果
经计算,本发明所述营养剂每100ml的能量为129.8kcal,即:
3.60*9+17.85*4+6.5*4=129.8kcal,其中:
蛋白质供能为6.5*4=26kcal,占总能量的20%;
脂肪供能为3.60*9=32.4kcal,占总能量的25%;
碳水化合物供能为17.85*4=71.4kcal,占总能量的55%。
总之,以上对本发明具体实施方式的描述并不限制本发明,本领域技术人员可以根据本发明作出各种改变或变形,只要不脱离本发明的精神,均应属于本发明所附权利要求的范围。
Claims (8)
1.一种适用于肝癌患者的肠内营养剂,所述营养剂包含蛋白质、脂肪、碳水化合物、膳食纤维、牛磺酸、L-肉碱、酵母抽出物、酵母β-葡聚糖、枸杞多糖、维生素、矿物质和水;
其中,所述蛋白质包含乳清蛋白和支链氨基酸;
所述脂肪包含芥花油、中链脂肪酸甘油三酯和鱼油;
所述碳水化合物包含麦芽糊精和水解米粉;
所述膳食纤维包含低聚果糖;
所述维生素包含维生素A、维生素D、维生素E、维生素K1、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、生物素、氯化胆碱、烟酸、叶酸和泛酸;
所述矿物质包含L-乳酸钙、氯化钠、磷酸氢二钾、硫酸铜、氧化镁、硫酸亚铁、硫酸锌、硫酸锰、磷酸钙、碘化钾、氯化钾、硒酸钠、钼酸钠、三氯化铬;
优选地,按所述营养剂1000mL计,所述营养剂包含:蛋白质50-75g、脂肪30-48g、碳水化合物158-186g、膳食纤维9-18g、牛磺酸171-319mg、L-肉碱100-156mg、核苷酸(来源于酵母抽出物)300-419mg、酵母β-葡聚糖150-320mg、枸杞多糖0.8-1.5g、维生素0.5-2g、矿物质13.8-25.8g、水650-710g;
优选地,按所述营养剂1000mL计,所述营养剂包含:蛋白质65g、脂肪36g、碳水化合物178g、膳食纤维13g、牛磺酸200mg、L-肉碱130mg、核苷酸320mg、酵母β-葡聚糖180mg、枸杞多糖1g、维生素1g、矿物质18.9g、水656g。
2.根据权利要求1所述的肠内营养剂,其特征在于,按所述营养剂1000mL计,所述蛋白质来源于乳清蛋白56.5-78g、支链氨基酸4.8-12.6g;优选地,所述蛋白质来源于乳清蛋白73.5g、支链氨基酸6.4g。
3.根据权利要求1或2所述的肠内营养剂,其特征在于,按所述营养剂1000mL计,所述脂肪来源于芥花油16.2-19.4g、中链甘油三酯13.3-16.4g、鱼油6.5-14.4g;优选地,所述脂肪来源于芥花油18.0g、中链甘油三酯16.0g、鱼油10g。
4.根据权利要求1至3中任一项所述的肠内营养剂,其特征在于,按所述营养剂1000mL计,所述碳水化合物来源于水解米粉80.5-125g、麦芽糊精76.8-112.5g;优选地,所述碳水化合物来源于水解米粉95.0g、麦芽糊精90.0。
5.根据权利要求1至4中任一项所述的肠内营养剂,其特征在于,按所述营养剂1000mL计,所述维生素包含维生素A 0.65-1.5mg RE、维生素D 9.2-20.1μg、维生素E 45-71mg α-TE、维生素K1 85-120μg、维生素B1 1-4mg、维生素B2 1.2-3.1mg、维生素B6 2-5.3mg、维生素B12 5.2-9.3μg、维生素C 176-258mg、生物素340-425μg、氯化胆碱352-486mg、烟酸22.3-28mg、叶酸384-610μg、泛酸9.2-16mg;
优选地,所述维生素来源于维生素A 0.94mg RE、维生素D 12.5μg、维生素E 117mg α-TE、维生素K1 100μg、维生素B1 1.88mg、维生素B2 24.9mg、维生素B6 2.5mg、维生素B12 7.6μg、维生素C 515mg、生物素377μg、氯化胆碱374mg、烟酸25mg、叶酸380μg、泛酸12.6mg。
6.根据权利要求1至5中任一项所述的肠内营养剂,其特征在于,按所述营养剂1000mL计,所述矿物质包含L-乳酸钙2.1-2.8g、氯化钠2.8-3.5g、磷酸氢二钾0.8-1.35g、硫酸铜1.5-2.4mg、氧化镁0.38-0.54g、硫酸亚铁42-63mg、硫酸锌88-116mg、硫酸锰16.8-23.2mg、磷酸钙1-1.8g、碘化钾0.22-0.36mg、氯化钾0.42-0.54g、硒酸钠0.48-0.67mg、钼酸钠0.38-0.52mg、三氯化铬4.8-7.2mg;
优选地,按所述营养剂1000mL计,所述矿物质来源L-乳酸钙2.5g、氯化钠3.2g、磷酸氢二钾1.2g、硫酸铜2mg、氧化镁0.5g、硫酸亚铁50mg、硫酸锌100mg、硫酸锰20mg、磷酸钙1.45g、碘化钾0.3mg、氯化钾0.48g、硒酸钠0.55mg、钼酸钠0.45mg、三氯化铬6mg;
优选地,所述营养剂还包含乳化剂,其选自卵磷脂、单,双甘油脂肪酸酯、琥珀酸单甘油酯中的一种或多种;
优选地,按所述营养剂1000mL计,所述营养剂包含乳化剂3.3g;
优选地,所述营养剂还包含调味品,其选自天然香草和人工香草中的一种或两种。
7.根据权利要求1至6中任一项所述的肠内营养剂,其特征在于,所述营养剂包含的蛋白质、脂肪和碳水化合物的供能比为16-22%∶20-28%∶50-64%,优选地,所述营养剂包含的蛋白质、脂肪和碳水化合物的供能比为20%∶25%∶55%。
8.权利要求1至7中任一项所述的肠内营养剂的制备方法,制备方法包括将上述各成分混合均匀;
优选地,所述肠内营养剂的制备方法包括以下步骤:
(1)制备以下溶液:
溶液A:由脂肪(中链甘油三酯、芥花油、鱼油)、乳化剂和脂溶性维生素预混料组成,其中脂溶性维生素预混料由维生素A、维生素D、维生素E、维生素K1组成;
溶液B:由蛋白质(乳清蛋白、支链氨基酸)和水组成;
溶液C:由水、碳水化合物(麦芽糊精、水解淀粉)、膳食纤维(低聚果糖)、枸杞多糖和浓度为35%的氢氧化钾组成;
溶液D:由非脂溶性维生素(维生素C、氯化胆碱、烟酸、维生素B12、泛酸、维生素B1、维生素B6、维生素B2、叶酸、生物素)、酵母抽出物、牛磺酸、L-肉碱和水组成;
溶液E:由矿物质和水组成,优选由L-乳酸钙、氯化钠、磷酸氢二钾、硫酸铜、氧化镁、硫酸亚铁、硫酸锌、硫酸锰、磷酸钙、碘化钾、氯化钾、硒酸钠、钼酸钠、三氯化铬和水组成;
溶液F:由水和调味剂组成,优选由水、天然香料和人工香料组成;
将溶液A、B、C、D、E和F混合后在55-65℃下搅拌,调节pH至6.5-6.8;
(2)将步骤(1)得到的混合物加热至70-75℃,0.1-0.2MPa下脱气,后于8-10MPa下乳化后加热至98-102℃,后加热至146-147℃,保持3-8秒;
(3)将步骤(2)得到的混合物冷却至98-102℃;后基板散热降温至70-75℃。
(4)在氮气的保护下,将步骤(3)得到的混合物在30-50MPa压力下均质,后在70-80℃下保持13-20秒,后冷却至2-6℃,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510945183.9A CN106890312A (zh) | 2015-12-18 | 2015-12-18 | 一种适用于肝癌患者的肠内营养剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510945183.9A CN106890312A (zh) | 2015-12-18 | 2015-12-18 | 一种适用于肝癌患者的肠内营养剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106890312A true CN106890312A (zh) | 2017-06-27 |
Family
ID=59188951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510945183.9A Pending CN106890312A (zh) | 2015-12-18 | 2015-12-18 | 一种适用于肝癌患者的肠内营养剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106890312A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107691645A (zh) * | 2017-10-27 | 2018-02-16 | 丘少荣 | 一种姬松茸复合饮料及其制备方法 |
CN108208798A (zh) * | 2017-12-29 | 2018-06-29 | 北京康爱营养科技股份有限公司 | 全营养配方液及其制备方法 |
CN108294306A (zh) * | 2018-04-03 | 2018-07-20 | 健行天下生物技术有限公司 | 一种氨基酸型全营养特殊医学用途配方食品 |
CN108308608A (zh) * | 2018-03-15 | 2018-07-24 | 北京康爱营养科技股份有限公司 | 一种适用于血液透析肾病患者的全营养配方液 |
CN108991500A (zh) * | 2018-07-02 | 2018-12-14 | 邦世迪(广东)医用食品股份有限公司 | 一种肿瘤病人用全营养配方食品 |
CN109349612A (zh) * | 2018-11-29 | 2019-02-19 | 徐州市迪港商贸有限公司 | 一种纯酰素抗癌复合酶配方 |
CN109588697A (zh) * | 2017-09-30 | 2019-04-09 | 江苏正大丰海制药有限公司 | 一种口服全营养组合物 |
CN109641055A (zh) * | 2017-07-20 | 2019-04-16 | 德尔塔菲制药股份有限公司 | 基于癌细胞代谢特异性的新颖抗恶性肿瘤剂 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190755A (en) * | 1988-03-09 | 1993-03-02 | Probi Ab | Nutrient composition and method for the preparation thereof |
CN1439299A (zh) * | 2003-03-18 | 2003-09-03 | 华瑞制药有限公司 | 供肿瘤患者使用的肠内全营养乳剂及其制造方法 |
CN102342913A (zh) * | 2011-09-06 | 2012-02-08 | 华瑞制药有限公司 | 供肿瘤患者使用的肠内营养乳剂及其制备方法 |
CN102872452A (zh) * | 2012-09-21 | 2013-01-16 | 中国人民解放军第三军医大学第三附属医院 | 一种低钠、低钾肠内全营养剂 |
CN102942635A (zh) * | 2012-11-22 | 2013-02-27 | 天津科技大学 | 一种高细胞凋亡诱导活性枸杞多糖的提取方法 |
CN103211225A (zh) * | 2005-10-26 | 2013-07-24 | 雅培制药有限公司 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
CN103609933A (zh) * | 2013-10-31 | 2014-03-05 | 湖北一半天制药有限公司 | 一种用于肿瘤患者的肠内营养乳剂 |
-
2015
- 2015-12-18 CN CN201510945183.9A patent/CN106890312A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190755A (en) * | 1988-03-09 | 1993-03-02 | Probi Ab | Nutrient composition and method for the preparation thereof |
CN1439299A (zh) * | 2003-03-18 | 2003-09-03 | 华瑞制药有限公司 | 供肿瘤患者使用的肠内全营养乳剂及其制造方法 |
CN103211225A (zh) * | 2005-10-26 | 2013-07-24 | 雅培制药有限公司 | 包含二十二碳六烯酸和叶黄素的婴儿配方 |
CN102342913A (zh) * | 2011-09-06 | 2012-02-08 | 华瑞制药有限公司 | 供肿瘤患者使用的肠内营养乳剂及其制备方法 |
CN102872452A (zh) * | 2012-09-21 | 2013-01-16 | 中国人民解放军第三军医大学第三附属医院 | 一种低钠、低钾肠内全营养剂 |
CN102942635A (zh) * | 2012-11-22 | 2013-02-27 | 天津科技大学 | 一种高细胞凋亡诱导活性枸杞多糖的提取方法 |
CN103609933A (zh) * | 2013-10-31 | 2014-03-05 | 湖北一半天制药有限公司 | 一种用于肿瘤患者的肠内营养乳剂 |
Non-Patent Citations (2)
Title |
---|
卢彦敏主编: "《临床内科常见病诊疗学》", 31 December 2011 * |
郭永等: "酵母β-葡聚糖的生物活性及开发利用", 《中国食物与营养》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109641055A (zh) * | 2017-07-20 | 2019-04-16 | 德尔塔菲制药股份有限公司 | 基于癌细胞代谢特异性的新颖抗恶性肿瘤剂 |
CN109588697A (zh) * | 2017-09-30 | 2019-04-09 | 江苏正大丰海制药有限公司 | 一种口服全营养组合物 |
CN107691645A (zh) * | 2017-10-27 | 2018-02-16 | 丘少荣 | 一种姬松茸复合饮料及其制备方法 |
CN108208798A (zh) * | 2017-12-29 | 2018-06-29 | 北京康爱营养科技股份有限公司 | 全营养配方液及其制备方法 |
CN108308608A (zh) * | 2018-03-15 | 2018-07-24 | 北京康爱营养科技股份有限公司 | 一种适用于血液透析肾病患者的全营养配方液 |
CN108294306A (zh) * | 2018-04-03 | 2018-07-20 | 健行天下生物技术有限公司 | 一种氨基酸型全营养特殊医学用途配方食品 |
CN108991500A (zh) * | 2018-07-02 | 2018-12-14 | 邦世迪(广东)医用食品股份有限公司 | 一种肿瘤病人用全营养配方食品 |
CN109349612A (zh) * | 2018-11-29 | 2019-02-19 | 徐州市迪港商贸有限公司 | 一种纯酰素抗癌复合酶配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106890312A (zh) | 一种适用于肝癌患者的肠内营养剂及其制备方法 | |
CN105054025B (zh) | 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂 | |
CN106616615A (zh) | 一种肿瘤专用型临床营养配方及其制备方法 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN106668835A (zh) | 一种用于肿瘤治疗的肠内营养剂及其制备方法 | |
JP2012197293A (ja) | 総合経腸栄養組成物 | |
CN108651988A (zh) | 肾病透析专用型临床营养配方及其制备方法 | |
CN103719875A (zh) | 一种用于糖尿病患者的肠内营养制剂 | |
CN103431392B (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
CN105533696A (zh) | 一种粉剂型肿瘤全营养配方食品 | |
CN105455133A (zh) | 一种预消化型全营养液及其制备方法 | |
CN104256610B (zh) | 一种辅助降血脂的保健组合物及软胶囊 | |
CN110742267B (zh) | 一种炎性肠病全营养配方食品 | |
CN109090580A (zh) | 一种用于肿瘤患者的特定全营养配方食品及其制备方法 | |
CN106165905B (zh) | 一种钙加维生素软胶囊及制备方法 | |
CN108308608A (zh) | 一种适用于血液透析肾病患者的全营养配方液 | |
CN107467193B (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
CN108902719A (zh) | 一种保健面条及其制备方法 | |
CN103082167B (zh) | 一种适用于艾滋病患者的复合型肠内营养制剂 | |
CN107028149A (zh) | 一种富铁保健盐及其制备方法 | |
CN103404875B (zh) | 一种供心血管疾病患者食用的复合海洋特膳食品 | |
CN105533721A (zh) | 翅果油口服乳及其制备方法 | |
CN107773754B (zh) | 一种用于机械通气患者的肠内营养组合物及其制备方法 | |
CN104738623A (zh) | 一种富含维生素k2和钙剂的香菇粉胶囊及其制备方法 | |
TWI743769B (zh) | 具有脂肪細胞專一性的微脂粒組成物及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: BEIJING KANG LOVE NUTRITION TECHNOLOGY CO., LTD. Document name: the First Notification of an Office Action |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170627 |